Recursion Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Synchrony Financial trades at $71.7 (market cap $24.69B). The key difference: Synchrony Financial is far larger — about 16.1× Recursion Pharmaceuticals Inc's market cap, and Synchrony Financial pays a 1.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SYF | |
|---|---|---|
Market Cap | $1.53B | $24.69B |
Sector | Health | Financials |
52-Week High | $6.79 | $88.47 |
52-Week Low | $2.84 | $63.78 |
Enterprise Value | $946.50M | — |
Dividend Yield | — | 1.63% |
Trailing returns across standard periods
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →